OurCongressPublic Data • Non-Partisan
Built to help voters quickly verify how officials vote — district first, party second. All information is sourced from official public records.
← Back to bills
HR. 1563 · 119th Congress

STOP Fentanyl and Xylazine Act

In committee

This bill has not become law. Status shown reflects the latest official action.

See what this could mean for your district

Save your district in Account to view district-specific context for this bill.

Set my district

Bill details

Introduced: 2/25/2025
Status: Referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Bill ID: 119hr1563
Latest action: Referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Summary

Introduced in House

Safeguarding Testing and Overdose Prevention Against Fentanyl and Xylazine Act or the STOP Fentanyl and Xylazine Act This bill exempts the possession, sale, purchase, import, export, or transport of equipment that tests for the presence of fentanyl or xylazine from criminal penalties under the Controlled Substances Act.

Source: BILLSUM · Summary date: 2/25/2025

District impact notes

1 notes
NEUTRAL
3/26/2026

The STOP Fentanyl and Xylazine Act allows for the legal possession and use of testing equipment for fentanyl and xylazine without criminal penalties. • This policy could facilitate local efforts in substance use prevention and overdose response by making testing equipment more accessible. • Local public health organizations may find it easier to implement testing programs, potentially impacting community health initiatives. • There may be questions about how this exemption will be enforced and whether it could lead to unintended consequences in the regulation of related substances. AI-generated from official bill summary and plain-English note; verify with official text.

Related votes

Roll calls that reference this bill in official data.

0 roll calls
No related roll calls found yet for this bill.

Primary sources

Official links to verify details. (No interpretation.)

Summary source label: BILLSUM
Congress.gov bill →GovInfo bill text (BILLS) →GovInfo summaries (BILLSUM) →OurCongress methodology →
About this data
  • OurCongress is non-partisan by design. We do not add political interpretation or advocacy.
  • Bill data and official summaries come from GovInfo and Congress.gov. Some bills do not have published summaries yet.
  • District impact notes (when shown) are AI-generated from official bill metadata/summaries to improve readability. They are not official government language.
  • This page updates automatically via a daily ingestion pipeline.

About this data

Non-partisan by design
OurCongress provides plain-English context without endorsements, political interpretation, or advocacy.
Official sources
Data is sourced from official government records (e.g., Congress.gov, GovInfo, Clerk of the House, and the U.S. Senate).
AI-generated text
Some sections may be AI-generated from official summaries/metadata to help readability. AI output can be imperfect—verify with primary sources.
Last updated: 3/26/2026Source: BILLSUMBill: 119hr1563Learn more →